Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are a type of white blood cell that are responsible for defending the body against infection. The most common forms of non-Hodgkin lymphoma are follicular (slower growing subtype) and diffuse large B-cell lymphoma (faster growing subtype). According to the American Cancer Society, nearly 70,000 people are expected to be diagnosed with non-Hodgkin lymphoma in the United States during 2013.

Non-Hodgkin Lymphoma Clinical Trials

Brentuximab vedotin phase 3 ALCANZA trial for patients with relapsed CD30-positive cutaneous T-cell lymphoma
Randomized trial evaluating brentuximab vedotin versus investigator's choice of methotrexate or bexarotene in patients with CD30-positive cutaneous T-cell lymphoma. (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001
Learn more

Brentuximab vedotin phase 3 ECHELON-2 trial for patients with newly diagnosed mature T-cell lymphomas
Randomized, double-blind trial comparing the efficacy and safety of brentuximab vedotin plus CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas. Study #SGN35-014
Learn more

Brentuximab vedotin phase 2 trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas
Evaluating the activity and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. Study #SGN35-012
Learn more

Brentuximab vedotin phase 2 trial for patients with newly diagnosed diffuse large B-cell lymphoma
Evaluating brentuximab vedotin in combination with standard of care treatment, RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), as frontline therapy in patients with diffuse large B-cell lymphoma (DLBCL). Study #SGN35-017
Learn more

SGN-CD19A phase 1 trial for B-lineage acute lymphoblastic leukemia and highly aggressive lymphomas
Open-label trial evaluating the safety, tolerability and antitumor activity of SGN-CD19A in B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) and highly aggressive lymphomas. Study #SGN19A-001
Learn more

SGN-CD19A phase 1 trial for relapsed or refractory B-lineage non-Hodgkin lymphoma
Open-label trial evaluating the safety, tolerability and antitumor activity of SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-002
Learn more

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com